new old challeng weigh
result start
water face new old challeng start featur
surprisingli sizabl top bottom line miss constant currenc growth
compar guidanc weak broad base across product
categori end market surpris given compani tone
appear upbeat recent analyst day believ sever issu
appear company-specif notabl water china busi declin due
restructur govern food safeti ministri well slower purchas gener
pharmaceut custom time food safeti commentari surpris
given agil first describ issu may rel peer
outsiz exposur gener given market leadership lc europ declin
ex-fx attribut uncertainti around macroeconom condit
brexit result contrast stabl trend report life scienc tool peer
last week ta product line declin ex-fx notabl pressur
tie europ follow retir ta presid top line
miss drove ep miss despit lower-than-expect tax rate
share count collect ad quarter vs forecast
weaker quarter lower forecast call
organ growth vs previous adj ep forecast
lower previou forecast ultim end market outlook
look posit despit short-term nois
biopharma continu
addit revenu base custom
sticki given regulatori
consider custom given signific buy-back author
come believ share find support near term
said believ imper water improv execut drive
success new product launch justifi signific buy-back program
ultim look better visibl new product view current
rel valuat vs peer appropri context adj ebitda
reiter equal weight rate though lower pt
quarterli annual ep usd
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
lower usd
return equiti ttm
link barclay live interact chart
equal weight admir track
record above-market revenu growth margin
given compani market domin
pharmaceut custom chromatographi
said balanc water success view
difficult gener sustain above-
market earn growth reflect
biopharma remain area strength higher
consum margin drive upsid
ebitda expect upsid ebitda
million yield upsid case
fund biotech pressur capit invest
life scienc tool drive downsid
ebitda estim downsid ebitda
million yield downsid case
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
water face new old challeng start featur surprisingli
sizabl top bottom line miss constant currenc growth compar
guidanc forecast midpoint weak broad base across
product categori end market surpris given compani tone
appear upbeat recent analyst day follow confer call
discuss manag believ sever issu appear company-
specif notabl water china busi declin due restructur
govern food safeti ministri well slower purchas gener pharmaceut
custom time food safeti commentari surpris given agil first
describ issu may rel peer outsiz exposur
gener given market leadership liquid chromatographi europ declin ex-
fx attribut uncertainti around macroeconom condit brexit
result contrast stabl trend report life scienc tool peer last week
ta product line declin ex-fx notabl pressur
aforement european market follow retir ta presid
top line miss drove ep miss despit lower-than-
expect tax rate share count collect ad quarter vs forecast
weaker quarter lower forecast call
organ growth vs previous adj ep forecast
lower previou forecast repres growth y/i
ultim end market outlook biopharma continu look posit despit
short term nois addit revenu base custom sticki given
regulatori consider custom given signific buy-back
author come believ share find support
near term said believ imper water improv execut
drive success new product launch justifi signific buy-back program
ultim look better visibl new product prospect view
current rel valuat vs peer appropri context adj ebitda
reiter equal weight rate though lower pt
lower price target given lower earn trajectori
increas caution outlook pt repres
adjust ebitda million prior price target repres prior
ebitda estim million
follow miss lower guidanc revenu
compani forecast organ growth vs previous fx forecast
headwind revenu growth drive total revenu year gross
margin expect previou guidanc net interest
expens expect approxim million million
increas result increment debt relat compani new leverag target
repurchas plan expect execut upon next two year guidanc
assum billion repurchas includ million would
bring compani weight averag share count million tax water
anticip non-gaap tax rate repres increas
midpoint guidanc call ep rang repres
guidanc
growth y/i foreign exchang expect headwind ep
guid toward organ revenu growth headwind
fx impli total revenu growth ep expect rang
fx expect headwind ep
revenu million expect million
constant currenc growth lower expect model
midpoint manag guidanc revenu repres
growth y/i ex-fx total declin fx headwind compar
compani guidanc million embed organ growth
fx headwind note advers impact less workday
quarter impact recur revenu quarter underli growth across
product segment weaker quarter rel expect instrument
y/i ex-fx recur revenu grew y/i ex-fx includ growth
servic chemistri weak instrument surpris given
face easi comparison quarter estim
instrument declin ex-fx quarter comp
end market perspect biopharma full-year sale end market
deliv ex-fx declin deceler growth compani
note softer expect demand china gener manufactur specif
gener manufactur slow rate capit purchas result
initi us note slower budget releas larg pharmaceut
compani importantli compani remain confid durabl small
molecul franchis notabl growth driver industri full-year
sale end market declin ex-fx y/i deceler growth
ta declin ex-fx within impli legaci water industri stronger
perform final academ full-year sale end market grew ex-fx y/i
compar organ growth water note strength healthi academ
trend us europ partial off-set weak chines food sector
remind segment volatil good read-through
coverag given greater instrument exposur govern exposur within
custom class
growth adj day barclay corp
growth across geograph end market mix asia growth driven
india japan south korea china declin weaker demand biopharma
food custom europ revenu declin cautiou macro outlook
impact purchas trend industri biopharma custom said saw
strength european academ govern end market america sale
flat us grew note solid growth industri academ
govern end market off-set softer demand biopharma
water geograph divers rev
water revenu breakdown end market
post weaker expect quarter biopharma organ
declin forecast growth demand lag china us
purchas trend slow larg pharmaceut custom gener manufactur
importantli trend india improv quarter broadli experienc
steadi trend across small molecul custom biopharma exposur
robust trend larg molecul custom confer call water ceo
chri oconnel note sale broadli defin pharmaceut categori flat
quarter demand custom larg molecul applic biomed
research strong off-set slower-than-expect budget releas largest
pharmaceut custom well gener manufactur china
target lc-m
biopharmaceut analyt solut well durabl franchis small
molecul test addit encourag return growth india
feel good strong posit
tool average includ agil thermo fisher
academ govern busi grew y/i organ quarter
healthi academ trend us europ partial off-set weak
chines food sector import rememb academ govern
segment lumpi gener great read-through peer
factor point compar academic/govern exposur peer
import rememb academ govern segment
lumpi gener great read-through peer factor point
compar academic/govern exposur peer
mix academic/govern exposur broader mani
peer compani nih busi also dod fbi usda
name gener nih repres academ govern revenu
remaind coverag
academ govern smallest custom class repres
total revenu gener academic/govern custom major util
chromatographi system also mean percentag revenu
consum servic stream lower area instead sale gener
driven high-end mass spectrometri placement lumpi quarterli
basi chromatographi largest product segment monitor
biopharma trend better read segment perform addit
natur market academ govern notabl sticki
trend tend vari per quarter
similarli less consum revenu academic/govern
custom class peer water broad consum stream lab
suppli sampl prep like thermo fisher agil drive consist
govern academ exposur
end market perform quarter
revenu grew organ water divis declin ta
water divis revenu growth ex-fx y/i divis revenu
million came million expect million
decreas y/i organ basi revenu increas y/i
estim chemistri revenu lower organ expect
versu expect organ instrument revenu
expect growth servic revenu increas
organ compar model currenc headwind segment
revenu quarter versu forecast manag
guidanc headwind
ta instrument divis revenu declin ex-fx y/i ta instrument
revenu million came million estim decreas
organ y/i versu forecast organ currenc headwind
quarter versu estim headwind
market y/i y/i growth y/i y/i growth y/i y/i growth y/i growth barclay corp
water revenu segment million
non-gaap ep increas y/i though impact lower
expect top line lower oper margin vs forecast partial
off-set lower expect tax rate share count note ep came
low end manag guidanc compani share count came
expect ad ep rel model lower tax
rate ad result adjust ep came meaning lower estim
water non-gaap ep growth
gross margin came expect compani
attribut quarter-specif mix lower fix cost absorpt gross margin
y/i full year compani guid investor gross
margin previou guidanc
water gross margin adjust ebitda
sg ex-stock comp expens flat y/i revenu
 expens total revenu y/i model rel
steadi expenditur compani continu invest intern growth
water adjust sg trend
adjust oper incom million declin y/i came
forecast oper margin y/i
estim lower expect top line growth gross margin drove
miss percentag revenu come estim
water ebit margin annual growth
deliv million cffo forecast exclud
million relat invest tandem precis chemistri
oper compani activ share repurchas repurchas share
model water continu execut billion share
repurchas author two year expect
water use oper million
 mm except ep reportedincom growth profit ebitda ebit debt pre-tax pre-tax tax net adj net researchprior yearprior quarter barclay corp
estestestestestestestincom statement growth growth growth growth growth growth y/i growth y/i organ adj growth product product product revenu inc product revenu inc servic servic gross gross margin inc gross margin inc growth growth y/i administr growth growth y/i base sg stock base oper growth growth y/i ebitda growth acquir intang oper incom ebit growth debt invest pre-tax pre-tax growth benefit incom tax net net growth adj adj barclay corp
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
